{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T16:58:57Z","timestamp":1792083537988,"version":"4.4.0"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2027,2,1]],"date-time":"2027-02-01T00:00:00Z","timestamp":1801440000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2027,2,1]],"date-time":"2027-02-01T00:00:00Z","timestamp":1801440000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T00:00:00Z","timestamp":1786924800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007606","name":"Aarhus Universitetshospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007606","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinica Chimica Acta"],"published-print":{"date-parts":[[2027,2]]},"DOI":"10.1016\/j.cca.2026.121276","type":"journal-article","created":{"date-parts":[[2026,8,16]],"date-time":"2026-08-16T12:04:47Z","timestamp":1786881887000},"page":"121276","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Impact of renal impairment, hepatic function, and circadian rhythm on pre-treatment plasma uracil levels"],"prefix":"10.1016","volume":"593","author":[{"given":"Malene H.","family":"Kirkeby","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Greibe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elke","family":"Hoffmann-L\u00fccke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cca.2026.121276_bb0005","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ctrv.2016.08.002","article-title":"Improving safety of fluoropyrimidine chemotherapy by individualizing treatment based on dihydropyrimidine dehydrogenase activity - ready for clinical practice?","volume":"50","author":"Meulendijks","year":"2016","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.cca.2026.121276_bb0010","doi-asserted-by":"crossref","DOI":"10.1007\/s00280-026-04885-x","article-title":"Model-based meta-analysis of individual patient data for the characterization of intravenous 5-fluorouracil population pharmacokinetics","volume":"96","author":"Briki","year":"2026","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.cca.2026.121276_bb0015","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S0065-2571(00)00011-X","article-title":"Importance of dihydropyrimidine dehydrogenase (DPD) deficiency in patients exhibiting toxicity following treatment with 5-fluorouracil","volume":"41","author":"Johnson","year":"2001","journal-title":"Adv. Enzym. Regul."},{"key":"10.1016\/j.cca.2026.121276_bb0020","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0175998","article-title":"New advances in DPYD genotype and risk of severe toxicity under capecitabine","volume":"12","author":"Etienne-Grimaldi","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.cca.2026.121276_bb0025","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1172\/JCI113308","article-title":"Familial deficiency of dihydropyrimidine dehydrogenase. Biochemical basis for familial pyrimidinemia and severe 5-fluorouracil-induced toxicity","volume":"81","author":"Diasio","year":"1988","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.cca.2026.121276_bb0030","author":"European Medicines Agency"},{"key":"10.1016\/j.cca.2026.121276_bb0035","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0959-8049(99)00211-7","article-title":"Can dihydropyrimidine dehydrogenase impact 5-fluorouracil-based treatment?","volume":"36","author":"Milano","year":"2000","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.cca.2026.121276_bb0040","unstructured":"European Medicines Agency. Fluorouracil and fluorouracil-related substances \u2013 Article 31 referral. Annex III: Product information, 2026. https:\/\/www.ema.europa.eu\/en\/documents\/referral\/fluorouracil-and-fluorouracil-related-substances-article-31-referral-annex-iii_en.pdf, (accessed March 5 2026)."},{"key":"10.1016\/j.cca.2026.121276_bb0045","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1007\/s00280-021-04354-7","article-title":"Pretherapeutic screening for Dihydropyrimidine deshydrogenase deficiency in measuring uracilemia in dialysis patients leads to a high rate of falsely positive results","volume":"88","author":"Gaible","year":"2021","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.cca.2026.121276_bb0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.101577","article-title":"Impact of renal impairment on dihydropyrimidine dehydrogenase (DPD) phenotyping","volume":"8","author":"Royer","year":"2023","journal-title":"ESMO Open."},{"key":"10.1016\/j.cca.2026.121276_bb0055","doi-asserted-by":"crossref","DOI":"10.1177\/17588359221148536","article-title":"Renal impairment and abnormal liver function tests in pre-therapeutic phenotype-based DPD deficiency screening using uracilemia: a comprehensive population-based study in 1138 patients","volume":"15","author":"Callon","year":"2023","journal-title":"Ther. Adv. Med. Oncol."},{"key":"10.1016\/j.cca.2026.121276_bb0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.cca.2023.117326","article-title":"Screening for dihydropyrimidine dehydrogenase deficiency by measuring uracilemia in chronic kidney disease patients is associated with a high rate of false positives","volume":"543","author":"Narjoz","year":"2023","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.cca.2026.121276_bb0065","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1515\/cclm-2025-0949","article-title":"Impact of renal and hepatic function on dihydropyrimidine dehydrogenase phenotype assessed by enzyme activity in peripheral blood mononuclear cells and uracilemia","volume":"64","author":"Contu","year":"2026","journal-title":"Clin. Chem. Lab. Med."},{"key":"10.1016\/j.cca.2026.121276_bb0070","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1111\/bcp.15715","article-title":"Discrepancies between dihydropyrimidine dehydrogenase phenotyping and genotyping: what are the explanatory factors?","volume":"89","author":"Arriv\u00e9","year":"2023","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.cca.2026.121276_bb0075","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1111\/bcp.13007","article-title":"Pronounced between-subject and circadian variability in thymidylate synthase and dihydropyrimidine dehydrogenase enzyme activity in human volunteers","volume":"82","author":"Jacobs","year":"2016","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.cca.2026.121276_bb0080","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/sj.bjp.0705651","article-title":"Circadian rhythm of dihydrouracil\/uracil ratios in biological fluids: a potential biomarker for dihydropyrimidine dehydrogenase levels","volume":"141","author":"Jiang","year":"2004","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.cca.2026.121276_bb0085","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1080\/07420520500179969","article-title":"Circadian rhythm in dihydropyrimidine dehydrogenase activity and reduced glutathione content in peripheral blood of nasopharyngeal carcinoma patients","volume":"22","author":"Zeng","year":"2005","journal-title":"Chronobiol. Int."},{"key":"10.1016\/j.cca.2026.121276_bb0090","first-page":"197","article-title":"Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion","volume":"50","author":"Harris","year":"1990","journal-title":"Cancer Res."},{"key":"10.1016\/j.cca.2026.121276_bb0095","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.cca.2022.10.017","article-title":"Instability of uracil in whole blood might affect cancer treatment with fluoropyrimidines","volume":"538","author":"Tybirk","year":"2023","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.cca.2026.121276_bb0100","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1080\/00365510410006324","article-title":"The Nordic reference interval project 2000: recommended reference intervals for 25 common biochemical properties","volume":"64","author":"Rustad","year":"2004","journal-title":"Scand. J. Clin. Lab. Invest."},{"key":"10.1016\/j.cca.2026.121276_bb0105","article-title":"Plasma clearance of 5-fluorouracil is more influenced by variations in glomerular filtration rate than by uracil concentration","volume":"95","author":"Matheux","year":"2024","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.cca.2026.121276_bb0110","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1080\/0284186X.2022.2132117","article-title":"Dihydropyrimidine dehydrogenase (DPD) genotype and phenotype among Danish cancer patients: prevalence and correlation between DPYD-genotype variants and P-uracil concentrations","volume":"61","author":"Paulsen","year":"2022","journal-title":"Acta Oncol."},{"key":"10.1016\/j.cca.2026.121276_bb0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2025.115483","article-title":"Dose-individualisation of fluoropyrimidines based on pre-treatment serum uracil levels: the Alpe2U study","volume":"224","author":"Knikman","year":"2025","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.cca.2026.121276_bb0120","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1007\/s00280-021-04240-2","article-title":"Comparison of a thymine challenge test and endogenous uracil-dihydrouracil levels for assessment of fluoropyrimidine toxicity risk","volume":"87","author":"Burns","year":"2021","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.cca.2026.121276_bb0125","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1002\/cpt.2608","article-title":"Dihydropyrimidine dehydrogenase phenotyping using pretreatment uracil: a note of caution based on a large prospective clinical study","volume":"112","author":"de With","year":"2022","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.cca.2026.121276_bb0130","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1515\/cclm-2022-1167","article-title":"Short-term biological variation of plasma uracil in a Caucasian healthy population","volume":"61","author":"Winther-Larsen","year":"2023","journal-title":"Clin. Chem. Lab. Med."}],"container-title":["Clinica Chimica Acta"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898126004584?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898126004584?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T16:26:41Z","timestamp":1792081601000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009898126004584"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2027,2]]},"references-count":26,"alternative-id":["S0009898126004584"],"URL":"https:\/\/doi.org\/10.1016\/j.cca.2026.121276","relation":{},"ISSN":["0009-8981"],"issn-type":[{"value":"0009-8981","type":"print"}],"subject":[],"published":{"date-parts":[[2027,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of renal impairment, hepatic function, and circadian rhythm on pre-treatment plasma uracil levels","name":"articletitle","label":"Article Title"},{"value":"Clinica Chimica Acta","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cca.2026.121276","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"121276"}}